Physician profile

Rasbinder Singh

Physician Assistant · Bakersfield, CA

NPI 1609183680

$290.01

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$121.07

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Irhythm Technologies, INC. $89.37 2023-2024 Zio Xt Patch, Zio Monitor
Lilly USA, LLC $32.89 2022
Pfizer INC. $30.46 2021-2023
Bayer Healthcare Pharmaceuticals INC. $24.69 2022
Si-Bone, INC. $23.60 2021
Novartis Pharmaceuticals Corporation $22.54 2022
Gilead Sciences, INC. $18.27 2022
Shield Therapeutics INC $17.19 2023 Accrufer
Abbvie INC. $16.67 2021
Dexcom, INC. $14.33 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Rasbinder Singh

$290.01

in general payments reported 2019-2025

Years
2021-2024
Top company
Irhythm Technologies, INC.

https://glasscript.com/doctor/299056/rasbinder-singh

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.